*Titles, times, and locations may change. Check SABCS.org or the SABCS meeting platform and mobile app for the latest schedule.
GENERAL SESSION 1
Wednesday, December 6
9:00 a.m. – 12:00 p.m.
Hall 1
9:00–9:15 a.m. —GS01-01: Biomarker Results in high-risk estrogen receptor positive, human epidermal growth factor receptor 2 negative primary breast cancer following neoadjuvant chemotherapy ± nivolumab: an exploratory analysis of CheckMate 7FL
9:15–9:30 a.m. —GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756
9:30–9:45 a.m. — GS01-03: Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
9:45–10:00 a.m. — GS01-04: Discussant for GS01-01, GS01-02, and GS01-03
10:00–10:15 a.m. — GS01-05: Pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: Randomized open-label Phase 2 KEYLYNK-009 study
10:15–10:30 a.m. — GS01-06: Advancing evidence of the associations between specific benign breast diagnoses and future breast cancer risk
10:30–10:45 a.m. — GS01-07: Discussant for GS01-06
10:45–11:00 a.m. — GS01-08: CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer
11:00–11:15 a.m. — GS01-09: Discussant for GS01-08
11:15–11:30 a.m. — GS01-10: HER2CLIMB-02: Randomized, double-blind Phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer
11:30–11:45 a.m. — GS01-11: Discussant for GS01-10
Additional presentation to be announced
POSTER SPOTLIGHT SESSION #4: GAPS IN THE TIMING, TREATMENT SELECTION, AND SUPPORTIVE SERVICES FOR CANCER CARE
7:00 a.m. – 8:00 a.m.
Stars at Night Ballroom 3-4
Presentations:
PS04-01: Clinical impact of timing of systemic therapy in patients with early triple negative breast cancer
PS04-02: BRCA testing and PARP inhibitor utilization in real-world HER2-negative metastatic breast cancer
PS04-03: Survival benefit of regional nodal irradiation in clinically node-positive breast cancer following neoadjuvant chemotherapy and breast-conserving surgery
PS04-04: Adverse effects (AEs) reported via Patient Reported Outcome Measures (PROMs): A longitudinal analysis of the IMPORT HIGH breast radiotherapy trial (CRUK/06/003)
PS04-05: Discussant and panel discussion
PS04-06: Breast cancer recurrence among women with pre-diagnostic major depression and co-existing substance abuse disorder: A retrospective study in the United States Veterans Health Administration Cohort
PS04-07: Associations between virtual care access and psychological and mental health conditions among adults with breast cancer in the US: A population-based analysis
PS04-08: sociodemographic risk factors and prediction of aromatase inhibitor non-adherence in women with breast cancer enrolled in SWOG S1105
PS04-09: Patient-reported benefit of resources designed to assist with the financial toxicity of breast cancer
PS04-10: Discussant and panel discussion
POSTER SPOTLIGHT SESSION #5: SHINING A NEW LIGHT ON BREAST CANCER: NOVEL MOLECULAR AND FUNCTIONAL IMAGING APPROACHES TO DETECT AND CHARACTERIZE BREAST CANCER
7:00 a.m. – 8:00 a.m.
Hemisfair Ballroom 1-2
Presentations:
PS05-01: Accuracy and safety of fibroblast activation protein inhibitor (FAPI) PET/CT in diagnosis of axillary lymph node metastasis in early breast cancer patients: a prospective cohort study (PFB-01&02 study)
PS05-02: PET imaging of PARP expression as a biomarker of response to chemotherapy in breast cancer: A nonrandomized clinical trial
PS05-03: Magsense® HER2, a molecularly targeted magnetic resonance imaging agent for the detection of axillary nodal metastasis in subjects with human epidermal growth factor receptor 2 positive (HER2+) breast cancer
PS05-04: [89Zr]Trastuzumab-PET/MRI to characterize her2+ breast cancer: A quantitative approach on tumor heterogeneity
PS05-05: Discussant and panel discussion
PS05-06: Outcomes of surveillance using contrast enhanced mammography in women with a personal history of breast cancer
PS05-07: Early prediction of response to neoadjuvant immunotherapy in triple negative breast cancer (TNBC) with DCE-MRI
PS05-08: Restriction spectrum imaging MRI for automated evaluation of response to neoadjuvant therapy in breast cancer
PS05-09: A single-arm Phase II clinical study of fulvestrant combined with chemotherapy in the neoadjuvant treatment of HR+/HER2- locally advanced breast cancer
PS05-10: Discussant and panel discussion
POSTER SPOTLIGHT SESSION #6: PROGNOSTIC AND PREDICTIVE USES OF CELL FREE DNA
7:00 a.m. – 8:00 a.m.
Stars at Night Ballroom 1-2
Presentations:
PS06-01: Results from a pilot study exploring ctDNA detection using a tumor-informed assay in the monarchE trial of adjuvant abemaciclib with endocrine therapy in HR+, HER2-, node-positive, high-risk early breast cancer
PS06-02: Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy
PS06-03: Differences in ctDNA genomic profiles and outcomes of Black and White patients with metastatic breast cancer: results from a large multicenter consortium
PS06-04: The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial
PS06-05: Discussant and panel discussion
PS06-06: Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer
PS06-07: Liquid biopsy determination of HER2 status in breast cancer: results from a novel epigenomic platform
PS06-08: Longitudinal Neoadjuvant and Post-operative Evaluation of Circulating Tumor DNA in Early Breast Cancer using a Tumor-Informed Assay: Updated Analysis of the TRACER Cohort
PS06-09: Fragmentomic analysis of a circulating tumor DNA targeted cancer gene panel discriminates ER status in metastatic breast cancer liquid biopsies.
PS06-10: Discussant and panel discussion
POSTER SPOTLIGHT SESSION #7: PREVENTION
5:30 p.m. – 6:30 p.m.
Stars at Night Ballroom 3-4
Presentations:
PS07-01: Exemestane and breast cancer prevention: how low can we go? Drug and biomarker tissue levels in a randomized presurgical trial on exemestane alternative dosing regimen.
PS07-02: Benign breast disease and microcalcifications in percutaneous biopsies and breast cancer risk
PS07-03: Randomized trials of oestrogen-alone and breast cancer incidence: a meta-analysis
PS07-04: Improved uptake and adherence to prevention medication with use of baby tamoxifen in patients at high risk for breast cancer
PS07-05: Discussant and panel discussion
PS07-06: A novel citrullinated-ENO1 peptide-based vaccine for triple-negative breast cancer prevention
PS07-07: The RXR agonist, IRX4204, delays the formation of Brca1 mutant mammary tumors via modulation of the anti-tumor immune response
PS07-08: Bazedoxifene plus conjugated estrogen reduces mammary proliferation markers and improves adipocyte size, gut microbiome, and metabolic health: Findings from a preclinical model of obesity and breast cancer risk.
PS07-09: Prenatal BRCA1 epimutations is a major cause of triple-negative breast cancer
PS07-10: Discussant and panel discussion
POSTER SPOTLIGHT SESSION #8: ANTIBODY DRUG CONJUGATES: WHERE ARE WE HEADED?
5:30 p.m. – 6:30 p.m.
Hemisfair Ballroom 1-2
Presentations:
PS08-01: Antibody-Drug Conjugates (ADCs) in breast cancer: Real world analysis of outcomes
PS08-02: Efficacy of Sacituzumab-Govitecan (SG) post Trastuzumab-deruxtecan (T-DXd) and vice versa for HER2low advanced or metastatic breast cancer (MBC): a French multicentre retrospective study
PS08-03: Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): Multi-institution experience and biomarker analysis
PS08-04: Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
PS-08-05: Discussant and panel discussion
PS08-06: A Phase Ib/II Study to Assess the Safety and Efficacy of PM8002 (Anti-PD-L1 x VEGF-A Bispecific Antibody) in Combination with Nab-Paclitaxel for First Line Treatment of Locally Advanced or Metastatic Triple-Negative Breast Cancer
PS08-07: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Results from a phase 1 study.
PS08-08: Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in Phase 2 study
PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
PS08-10: Discussant and panel discussion
POSTER SPOTLIGHT SESSION #9: EXPLOITING TUMOR BIOLOGY IN HER2-POSITIVE BREAST CANCER TO ESCALATE OR DE-ESCALATE NEOADJUVANT THERAPY
5:30 p.m. – 6:30 p.m.
Stars at Night Ballroom 1-2
Presentations:
PS09-01: Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+ breast cancer in four trials of the West German Study Group
PS09-02: Event-free survival by Residual Cancer Burden (RCB) and intratumor her2 heterogeneity after neoadjuvant T-DM1 and pertuzumab for early-stage HER2-positive breast cancer
PS09-03: Neoadjuvant zanidatamab for stage I node negative HER2 positive breast cancer
PS09-04: The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: sub-analysis of the APHINITY trial
PS09-05: Discussant and panel discussion
PS09-06: Tumor infiltrating lymphocytes as a predictor of pathologic complete response to neoadjuvant therapy in HER2 positive breast cancer
PS09-07: SPAG5 as a companion prognostic and predictive test for management of early stage HER2 positive breast cancer (BCs)
PS09-08: Genomic characterization of endocrine resistance in ER+HER2+ breast cancers in the POETIC Trial
PS09-09: Multiomics profiling and molecular classification refine precision treatment strategies for HER2-positive breast cancer
PS09-10: Discussant and panel discussion
